Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector\u2122 Compositions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Ring Therapeutics

    Menu

    Ring Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ring Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines

              Details:

              The proceeds from the raise will advance Anellogy™ platform toward the clinic, transforming commensal anelloviruses into life-saving therapies, creating next-generation programable genetic medicines.

              Lead Product(s): Anellovirus-based Therapy

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alexandria Venture Investments

              Deal Size: $86.5 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing March 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ring Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector™ Compositions

              Details:

              Ring’s conception of Anellovectors™ as a broad bioplatform that could be applicable across diseases holds tremendous promise for unlocking the field of genetic medicines.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ring Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)

              Details:

              Data from poster presentation will illustrate that most anellovirus peptides are not associated with an antibody response in humans when compared to other known human viruses.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY